Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of RGX 121 in Ped

Indication
MPS II; Hunter Syndrome (MPS II)

Other upcoming events for RGNX

Patent ExpiryPatent/Exclusivity Expiry: ITOVEBI

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of RGX 121 in Ped — RGNX Phase 3 Readout | BioSniper